Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR
August 01, 2014
Wellesley, Mass., Aug 01, 2014 –BCC Research (www.bccresearch.com) reveals in its new report, RNAi DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS, the global market RNA interference (RNAi) drug delivery technologies is expected to grow to nearly $38.8 billion by 2018, with a five-year compound annual growth rate (CAGR) of 27.2%. The aptamer delivery category, the fastest moving segment of the market, is moving at a phenomenal 58.2% CAGR.
The field of RNAi therapeutics has shown tremendous growth and has moved toward clinical trials. Nonetheless, the development of RNAi therapeutics is dependent on safe, effective, and clinically suitable delivery carriers. The nanoparticle delivery category is the largest segment of the overall market and is expected to grow to $33.4 billion by 2018, registering a CAGR of 25%.
However, the aptamer delivery category, which was valued at just $218 million in 2013, is expected to jump to nearly $2.2 billion in 2018. Aptamers offer several advantages compared to protein or small-molecule drugs, most notably their ease of production, low risk of inducing an immune reaction in humans, and amenability to chemical modifications that enhance their drug-like properties, including improved stability and residence time in the bloodstream.
“There has been immense progress in the field of nanotechnology for drug delivery, and efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems,” says BCC Research biotechnology analyst Usha Nagavarapu. “A carefully engineered, multifunctional nanocarrier with targeting capabilities is needed to address the delivery challenges.”
The RNAi technologies market has application in the areas of therapeutics, research and development (functional genomics; metabolism), drug discovery, and agriculture. The therapeutics application market is focused on oncology, neurology, cardiology, ophthalmology, and metabolic disorders and is expected to grow in the next few years.
RNAi DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS provides an overview of the global market for RNAi drug delivery technologies. It includes analyses of global market trends, with data from 2010, 2012 and 2013, estimates for 2018, projections of CAGRs through 2018, and profiles of companies important in the industry.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.
RNAi Drug Delivery: Technologies and Global Markets( BIO076B )
Publish Date: Jun 2014
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
- China’s DNA Sequencing Market to Grow at 21.5% CAGR by 2030
- mRNA Market Forecast: Small Decline of -0.04% CAGR by 2030
- Molecular Diagnostics Market to Grow at 13.1% CAGR Through 2030
- Biotech Equipment Market Projected to Reach $143.9 Billion Globally by 2030
Reports from Cell Biology
Recent News
- Global Hyaluronic Acid in Healthcare Market to Reach $10.5 Billion by 2030
- Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030
- Global Market for Biological and Medical Imaging Reagents Set to Surge to $40.1 Billion by 2030
- Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030
- Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
